[Retracted] Distinct Molecular Subtypes of Diffuse Large B Cell Lymphoma Patients Treated with Rituximab-CHOP Are Associated with Different Clinical Outcomes and Molecular Mechanisms

Figure 7

Establishment and validation of a 10-gene signature for DLBCL. (a) Forest plot for the hazard ratio of the 10 genes in this signature. (b, c) Kaplan-Meier curves of overall survival in the (b) training and (c) validation sets.

(a)

(b)

(c)